RxDoctor Payments DataLook up a doctor →

Yoann Millet, MD

Interventional Pain Medicine · Shenandoah, TXNPI 1790027167

Payments from drug & device makers

$21,768in general payments, 2019–2025

Across 615 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Medtronic$5K
  • MML US, Inc.$2K
  • Tersera Therapeutics LLC$667
  • Indivior Inc.$567
  • AbbVie$558
  • plus $5K from 53 others

What the payments were for

  • Travel & lodging$2,87114%
  • Food & beverage$16,97386%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,768 in reported general payments places this provider in the 75th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$475,033
Medicare patients
180
Services billed
8,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl201$54,581
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,233$32,534
RelistorMethylnaltrexone Bromide12$28,814
Buprenorphine103$27,310
BelbucaBuprenorphine Hcl14$13,036
Lidocaine84$9,635
MovantikNaloxegol Oxalate16$6,255
LinzessLinaclotide12$6,084
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen222$6,026
Pregabalin412$6,014
Xtampza ErOxycodone Myristate11$5,856
Gabapentin342$5,577
Acetaminophen-CodeineAcetaminophen With Codeine162$3,571
Tizanidine Hcl276$3,394
Cyclobenzaprine Hcl239$2,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$305$28,81412 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$220$18,89125 claims
AbbVieLinzess$558$6,08412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →